|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Gene-expression profiles in lung cancer cell lines and surgically resected lung AC revealed that KRAS-G12C mutants had an epithelial to mesenchymal transition and a KRAS-independent phenotype.
|
25170638 |
2014 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S).
|
26920031 |
2016 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Our study demonstrated that TRAIL significantly suppressed cell survival, by inducing apoptosis in a dose-dependent manner, in the pancreatic cancer BxPC-3 (wild type G12) and lung cancer A549 (G12S) cell lines.
|
20848283 |
2011 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Although this mutation in KRAS accounts for 11% of all KRAS mutations in cancer, it is the most prominent KRAS mutant in lung cancer suggesting that G12C-specific inhibitors may provide a new approach for treating the subset of lung cancer patients harboring this mutant allele.
|
30366101 |
2019 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
We developed an integrative pharmacogenomics analysis to identify potential drug targets to overcome MEK/ERK inhibitor resistance in lung cancer cell lines with KRAS(G12C) mutation (n = 12).
|
31668570 |
2019 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Adding mTOR and IGF1R inhibitors to ARS-1620 greatly improves its effectiveness on KRAS-G12C mutant lung cancer cells in vitro and in mouse models.
|
31534020 |
2019 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Next generation sequencing performed on the Ion Torrent platforms by the Ion Ampliseq Colon and Lung Cancer panel showed a similar genomic profile in both neoplastic sites with a concurrent KRAS G12C mutation.
|
25900221 |
2015 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
As a result, 15 SNPs on or near 12 genes and one miRNA with strong evidence of association with lung cancer risk were identified, including TERT (rs2736098), CHRNA3 (rs1051730), AGPHD1 (rs8034191), CLPTM1L (rs401681 and rs402710), BAT3 (rs3117582), TRNAA (rs4324798), ERCC2 (Lys751Gln), miR-146a2 (rs2910164), CYP1B1 (Arg48Gly), GSTM1 (null/present), SOD2 (C47T), IL-10 (-592C/A and -819C/T), and TP53 (intron 6).
|
29110844 |
2017 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
However, rs7452888 (6q27) was identified as a possible candidate SNP to influence lung cancer survival, while stratified analysis hinted at a possible role for rs8034191</span>, rs16969968 (15q25.1) and rs4324798 (6p22.1) in influencing survival time in lun</span>g cancer patients who were never-smokers, based on a small sample.
|
21750227 |
2011 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here, the authors apply a novel method for mediation analysis, allowing for gene-environment interaction, to a lung cancer case-control study (1992-2004) conducted at Massachusetts General Hospital using 2 single nucleotide polymorphisms, rs8034191 and rs1051730, on 15q25.1.
|
22306564 |
2012 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
The potential association of three polymorphisms in the CHRNA3 (rs1051730(G > A)), CHRNA5 (rs16969968(G > A)), and AGPHD1 (rs8034191(A > G)) with the lung cancer risk has been widely investigated, but the results are inconsistent.
|
27072204 |
2016 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Similarly, neither CHRNA3 rs8034191 nor rs1051730 were associated with lung cancer risk.
|
20068085 |
2010 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
A meta-analysis provided increased support that variation at 15q25.1 (rs8034191; P = 3.24 x 10(-26)), 5p15.33 (rs4975616; P = 2.99 x 10(-9)), and 6p21.33 (rs3117582; P = 4.46 x 10(-10)) influences lung cancer risk.
|
19654303 |
2009 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
We found that 2 risk single nucleotide polymorphisms reported in the lung cancer GWA studies-rs8034191: A>G and rs1051730: G>A, located in this 15q24-25.1 region-were not associated with risk of pancreatic cancer.
|
21697764 |
2011 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
The association between rs8034191 and lung cancer risk was significant using multiple genetic models, suggesting that rs8034191 is a risk factor for lung cancer.
|
25854352 |
2015 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
In conclusion, this meta-analysis demonstrated that the two common variations (rs8034191 and rs1051730) at 15q25 are a risk factor associated with increased LC susceptibility, but these associations vary in different ethnic populations.
|
24254305 |
2014 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
There was no overall association between variant rs8034191 and lung cancer risk under the allele frequency model (OR = 1.03, 95 % CI = 0.93-1.13, P heterogeneity = 0.522).
|
25074529 |
2014 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
We evaluated five of the top candidate SNPs (rs402710, rs2736100, rs4324798, rs16969968, and rs8034191) for their effects on lung cancer risk and overall survival.
|
20056643 |
2010 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
The goal of this study was to determine whether recently identified genetic variation in 3 SNPs (rs1051730, rs931794, rs8034191) on chromosome 15q25.1 contributes to risk of lung cancer in African Americans.
|
19641473 |
2009 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our findings demonstrated that CHRNA3 gene rs1051730-A allele and AGPHD1 gene rs8034191-T allele might be risk-conferring factors for the development of lung cancer in Caucasians, but not in East-Asians.
|
22701590 |
2012 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Diplotype analysis of rs3841324 with either rs16969968 or rs8034191 showed that these polymorphisms influenced the lung cancer risk independently.
|
22028403 |
2011 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
However, no significant association was found between rs8034191T/C and LC risk.
|
23359026 |
2013 |
|
rs8034191
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
The risk of lung cancer was more than fivefold higher among those subjects who had both a family history of lung cancer and two copies of high-risk alleles rs8034191 (odds ratio [OR] = 7.20, 95% confidence interval [CI] = 2.21 to 23.37) or rs1051730 (OR = 5.67, CI = 2.21 to 14.60, both of which were located in the 15q24-25.1 locus, than among control subjects.
|
18780872 |
2008 |
|
rs401681
|
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our findings demonstrated that rs402710 and rs401681 are risk-conferring factors for the development of lung cancer.
|
24907075 |
2014 |